KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Treasury Shares: 2009-2024

Historic Treasury Shares for Teva Pharmaceutical Industries (TEVA) over the last 15 years, with Dec 2024 value amounting to $107.0 million.

  • Teva Pharmaceutical Industries' Treasury Shares changed negligibly% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $4.1 billion for FY2024, which is negligibly% changed negligibly from last year.
  • Teva Pharmaceutical Industries' Treasury Shares amounted to $4.1 billion in FY2024, which was down 0.00% from $4.1 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Treasury Shares' 5-year high stood at $4.1 billion during FY2020, with a 5-year trough of $4.1 billion in FY2020.
  • For the 3-year period, Teva Pharmaceutical Industries' Treasury Shares averaged around $81.8 million, with its median value being $106.0 million (2023).
  • Data for Teva Pharmaceutical Industries' Treasury Shares shows a peak YoY surged of 228.15% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Treasury Shares stood at $20.7 million in 2020, then increased by 17.82% to $24.4 million in 2021, then spiked by 32.32% to $32.3 million in 2022, then surged by 228.15% to $106.0 million in 2023, then climbed by 0.94% to $107.0 million in 2024.